T, creating opportunities in earlier treatment, off-the-shelf platforms and CD7 targeting, while relapse, toxicity and manufacturing remain key unmet needs.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- ...

Phase I results suggest XmAb18968 is tolerable and may have antileukaemic activity in relapsed or refractory AML and T-ALL.

Real-world outcomes of cytarabine consolidation in older patients with acute myeloid leukemia. Outcomes for adults with KMT2A-r acute myeloid leukemia treated with venetoclax plus azacitidine (Ven/Aza ...

Hannah Koepsell was 11 years old when she was diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. Two years of chemotherapy followed, and in 2024, she rang the ...

Add Yahoo as a preferred source to see more of our stories on Google. Medical Watch Digest for Dec. 9 Survival rates for childhood leukemia are improving thanks to new treatments. Acute lymphoblastic ...

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...

Miles Ramsey is a spirited young boy from Bondurant, Iowa. "He's got a spicy look to him," said his mother, Ali Ramsey, who ...